Advertisement
Screener

ENANTA PHARMACEUTICALS, INC (ENTA) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

1.6 / 5 stars · 38/120 Roast Me

ENANTA PHARMACEUTICALS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

ENANTA PHARMACEUTICALS, INC (ENTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 23.00 thousand shares for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-12

  • ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 10.00K shares, a 76.74% decline year-over-year.
  • ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 144.00K shares, a 171.70% increase year-over-year.
  • ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 43.00K shares, a 72.96% decline year-over-year.
  • ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 28.00K shares, a 62.16% decline year-over-year.
  • ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 232.00K shares, a 56.23% decline from fiscal 2024.
  • ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 530.00K shares, a 97.03% increase from fiscal 2023.
  • ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 269.00K shares, a 13.98% increase from fiscal 2022.
  • ENANTA PHARMACEUTICALS, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 236.00K shares, a 29.67% increase from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month
2026-06-3010.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-12
23.00K shares
10-Q · filed 2026-08-12
2026-03-3113.00K shares
10-Q · filed 2026-05-13
2025-09-30144.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19
187.00K shares
derived: sum of 2 quarters · filed 2025-11-19
215.00K shares
derived: sum of 3 quarters · filed 2025-11-19
232.00K shares
10-K · filed 2025-11-19
2025-06-3043.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-13
71.00K shares
derived: sum of 2 quarters · filed 2025-08-13
88.00K shares
10-Q · filed 2025-08-13
141.00K shares
derived: sum of 4 quarters · filed 2025-08-13
2025-03-3128.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14
45.00K shares
10-Q · filed 2025-05-14
98.00K shares
derived: sum of 3 quarters · filed 2025-05-14
257.00K shares
derived: sum of 4 quarters · filed 2025-05-14
2024-12-3117.00K shares
10-Q · filed 2025-02-12
70.00K shares
derived: sum of 2 quarters · filed 2025-02-12
229.00K shares
derived: sum of 3 quarters · filed 2025-02-12
303.00K shares
derived: sum of 4 quarters · filed 2025-02-12
2024-09-3053.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-27
212.00K shares
derived: sum of 2 quarters · filed 2024-11-27
286.00K shares
derived: sum of 3 quarters · filed 2024-11-27
530.00K shares
10-K · filed 2024-11-27
2024-06-30159.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-07
233.00K shares
derived: sum of 2 quarters · filed 2024-08-07
477.00K shares
10-Q · filed 2024-08-07
2024-03-3174.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-08
318.00K shares
10-Q · filed 2024-05-08
2023-12-31244.00K shares
10-Q · filed 2024-02-08
2023-09-30269.00K shares
10-K · filed 2023-11-22
2023-03-31125.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
169.00K shares
10-Q · filed 2023-08-08
82.00K shares
10-Q · filed 2023-05-09
256.00K shares
derived: sum of 3 quarters · filed 2023-08-08
309.00K shares
derived: sum of 4 quarters · filed 2023-08-08
2022-12-3144.00K shares
10-Q · filed 2023-02-08
131.00K shares
derived: sum of 2 quarters · filed 2023-02-08
184.00K shares
derived: sum of 3 quarters · filed 2023-02-08
246.00K shares
derived: sum of 4 quarters · filed 2023-02-08
2022-09-3087.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-23
140.00K shares
derived: sum of 2 quarters · filed 2022-11-23
202.00K shares
derived: sum of 3 quarters · filed 2022-11-23
236.00K shares
10-K · filed 2022-11-23
2022-06-3053.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08
115.00K shares
derived: sum of 2 quarters · filed 2022-08-08
149.00K shares
10-Q · filed 2022-08-08
192.00K shares
derived: sum of 4 quarters · filed 2022-08-08
2022-03-3162.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-09
96.00K shares
10-Q · filed 2022-05-09
139.00K shares
derived: sum of 3 quarters · filed 2022-05-09
173.00K shares
derived: sum of 4 quarters · filed 2022-05-09
2021-12-3134.00K shares
10-Q · filed 2022-02-10
77.00K shares
derived: sum of 2 quarters · filed 2022-02-10
111.00K shares
derived: sum of 3 quarters · filed 2022-02-10
157.00K shares
derived: sum of 4 quarters · filed 2022-02-10
2021-09-3043.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24
77.00K shares
derived: sum of 2 quarters · filed 2021-11-24
123.00K shares
derived: sum of 3 quarters · filed 2021-11-24
182.00K shares
10-K · filed 2021-11-24
2021-06-3034.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09
80.00K shares
derived: sum of 2 quarters · filed 2021-08-09
139.00K shares
10-Q · filed 2021-08-09
184.00K shares
derived: sum of 4 quarters · filed 2021-08-09
2021-03-3146.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-10
105.00K shares
10-Q · filed 2021-05-10
150.00K shares
derived: sum of 3 quarters · filed 2021-05-10
203.00K shares
derived: sum of 4 quarters · filed 2021-05-10
2020-12-3159.00K shares
10-Q · filed 2021-02-09
104.00K shares
derived: sum of 2 quarters · filed 2021-02-09
157.00K shares
derived: sum of 3 quarters · filed 2021-02-09
234.00K shares
derived: sum of 4 quarters · filed 2021-02-09
2020-09-3045.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-25
98.00K shares
derived: sum of 2 quarters · filed 2020-11-25
175.00K shares
derived: sum of 3 quarters · filed 2020-11-25
198.00K shares
10-K · filed 2020-11-25
2020-06-3053.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-10
130.00K shares
derived: sum of 2 quarters · filed 2020-08-10
153.00K shares
10-Q · filed 2020-08-10
184.00K shares
derived: sum of 4 quarters · filed 2020-08-10
2020-03-3177.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-11
100.00K shares
10-Q · filed 2020-05-11
131.00K shares
derived: sum of 3 quarters · filed 2020-05-11
147.00K shares
derived: sum of 4 quarters · filed 2020-05-11
2019-12-3123.00K shares
10-Q · filed 2020-02-10
54.00K shares
derived: sum of 2 quarters · filed 2020-02-10
70.00K shares
derived: sum of 3 quarters · filed 2020-02-10
96.00K shares
derived: sum of 4 quarters · filed 2020-02-10
2019-09-3031.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27
47.00K shares
derived: sum of 2 quarters · filed 2019-11-27
73.00K shares
derived: sum of 3 quarters · filed 2019-11-27
79.00K shares
10-K · filed 2019-11-27
2019-06-3016.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09
42.00K shares
derived: sum of 2 quarters · filed 2019-08-09
48.00K shares
10-Q · filed 2019-08-09
73.00K shares
derived: sum of 4 quarters · filed 2019-08-09
2019-03-3126.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-10
32.00K shares
10-Q · filed 2019-05-10
57.00K shares
derived: sum of 3 quarters · filed 2019-05-10
59.00K shares
derived: sum of 4 quarters · filed 2019-05-10
2018-12-316.00K shares
10-Q · filed 2019-02-08
31.00K shares
derived: sum of 2 quarters · filed 2019-02-08
33.00K shares
derived: sum of 3 quarters · filed 2019-02-08
44.00K shares
derived: sum of 4 quarters · filed 2019-02-08
2018-09-3025.00K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29
27.00K shares
derived: sum of 2 quarters · filed 2018-11-29
38.00K shares
derived: sum of 3 quarters · filed 2018-11-29
51.00K shares
10-K · filed 2018-11-29
2018-06-302.00K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-09
13.00K shares
derived: sum of 2 quarters · filed 2018-08-09
26.00K shares
10-Q · filed 2018-08-09
31.34K shares
derived: sum of 4 quarters · filed 2018-08-09
2018-03-3111.00K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-10
24.00K shares
10-Q · filed 2018-05-10
29.34K shares
derived: sum of 3 quarters · filed 2018-05-10
56.40K shares
derived: sum of 4 quarters · filed 2018-05-10
2017-12-3113.00K shares
10-Q · filed 2018-02-09
18.34K shares
derived: sum of 2 quarters · filed 2018-02-09
45.40K shares
derived: sum of 3 quarters · filed 2018-02-09
148.97K shares
derived: sum of 4 quarters · filed 2018-02-09
2017-09-305.34K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11
32.40K shares
derived: sum of 2 quarters · filed 2017-12-11
135.97K shares
derived: sum of 3 quarters · filed 2017-12-11
138.00K shares
10-K · filed 2017-12-11
2017-06-3027.06K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-09
130.63K shares
derived: sum of 2 quarters · filed 2017-08-09
132.66K shares
10-Q · filed 2017-08-09
141.28K shares
derived: sum of 4 quarters · filed 2017-08-09
2017-03-31103.57K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-10
105.60K shares
10-Q · filed 2017-05-10
114.22K shares
derived: sum of 3 quarters · filed 2017-05-10
131.12K shares
derived: sum of 4 quarters · filed 2017-05-10
2016-12-312.03K shares
10-Q · filed 2017-02-09
10.66K shares
derived: sum of 2 quarters · filed 2017-02-09
27.55K shares
derived: sum of 3 quarters · filed 2017-02-09
43.66K shares
derived: sum of 4 quarters · filed 2017-02-09
2016-09-308.63K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09
25.52K shares
derived: sum of 2 quarters · filed 2016-12-09
41.63K shares
derived: sum of 3 quarters · filed 2016-12-09
47.16K shares
10-K · filed 2016-12-09
2016-06-3016.89K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09
33.00K shares
derived: sum of 2 quarters · filed 2016-08-09
38.53K shares
10-Q · filed 2016-08-09
2016-03-3116.10K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10
21.64K shares
10-Q · filed 2016-05-10
2015-12-315.53K shares
10-Q · filed 2016-02-09
2015-09-3041.92K shares
10-K · filed 2015-12-11
2014-09-307.56K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11
7.63K shares
derived: sum of 2 quarters · filed 2014-12-11
16.91K shares
10-K · filed 2014-12-11
2014-06-3064.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-12
9.34K shares
10-Q · filed 2014-08-12
2014-03-319.28K shares
10-Q · filed 2014-05-12
2013-09-3011.32K shares
10-K · filed 2013-12-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Emergent BioSolutions Inc. (EBS)United States$0.347B-2.43
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
Rezolute, Inc. (RZLT)United States$0.382B-6.45
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63